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Summary 
Natural killer (NK) cells and some T  cells are endowed with receptors specific for class I major 
histocompatibility complex (MHC)  molecules that can inhibit cellular effector functions. The 
function of the  Ly49 receptor family has been studied  in vitro,  but no gene transfer  experi- 
ments have directly established the role of these receptors in NK cell functions. We show here 
that  transgenic  expression  of the  H-2Dd-specific Ly49A receptor In all  NK cells  and  T  cells 
conferred class  I-specific Inhibition  of NK cell-mediated  target  cell lysis  as well  as  of T  cell 
proliferation.  Furthermore, transgene expression prevented NK cell-mediated rejection of allo- 
geneic H-2  d bone marrow grafts by irradiated mice. These results demonstrate the function and 
specificity of Ly49 receptors in VlVO, and establish that their subset-specific expression is neces- 
salt for the discrimination of MHC-dlfferent cells by NK cells in unmampulated mice. 
T 
wo  families  of NK  cell  receptors  with  specificity  ~br 
MHC  class  I  molecules  have been  described.  Immu- 
noglobulin-like killer inhibitory receptors (KIl<s) were identi- 
fied on human NK cells,  whereas the structurally unrelated 
Ly49 family  of receptors,  homologous  to  C-type lectins, 
were  identified  in the  mouse  (1,  2).  The  Ly49 receptor 
family comprises eight closely related genes (Ly49A-H) on 
mouse chromosome 6  (2).  Expression of Ly49 receptors is 
largely restricted to NK cells and a small fraction of T  cells 
(3-5). The Ly49A, Ly49C, and Ly49G2 receptors are each 
expressed by 20-50% of NK cells,  with some cells  express- 
ing two  or even all  three  of the  receptors  (6-10).  Mouse 
NK cells  expressing the Ly49A receptor are unable  to kill 
H-2D  d- and  H-2Dk-expresslng tumor cell or lymphoblast 
target cells  (3,  11).  Evidence  that Ly49A binds  to D d,  and 
that anti-Ly49A antibodies  allow Ly49A  +  NK cells  to kill 
Dd-expressing  target  cells,  suggested  that  Ly49A is  a  D d- 
specific  receptor  that  delivers  an  inhibitory  signal  to  NK 
cells  (3,  12,  13).  NK cell subsets  expressing the  Ly49C or 
Ly49G2  receptors  are  inhibited  by  distinct  MHC  class  I 
molecules, K b for the B6 allele  of Ly49C and D d or L d for 
Ly49G2 (7,  9). 
To  date,  there  is  no  evidence  that  genetic  transfer  of 
Ly49  receptors  confers  class  I-specific  inhibition.  There- 
fore, the role of Ly49 receptors in regulating the various ef- 
fector functions ascribed to NK cells remains unclear.  This 
is particularly true for in vivo effector functions such as the 
NK cell-mediated rejection of bone marrow cells.  Further- 
more,  the  possibility  has  been  raised  that  Ly49  receptors 
play a role as accessory receptors in class  I-specific inhibi- 
non,  rather than as the primary determinants  of specificity 
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(14). These concerns are enhanced by the failure to date to 
isolate  munne  homologues  of the  human  KIP.  family  of 
class I-specific inhibitory receptors.  It remains possible that 
the two receptor families coexist in mice and mediate  dis- 
tinct  functions.  To  address  directly  the  role  of Ly49A in 
class  1-specific inhibition  of NK and  T  cell functions,  we 
have generated transgenic mice in which the Ly49A cDNA 
is expressed by all NK cells  and T  cells.  Transgenic expres- 
sion  of Ly49A in  all NK cells  from H-2  b mice prevented 
these mice from rejecting an H-2  d bone marrow allograft, 
and  resulted  in impaired  in vitro  cytolysis of tumor target 
cells expressing the D d Ly49A ligand. Furthermore,  expres- 
sion of Ly49A in T  cells specifically inhibited their capacity 
to  mount  a  proliferative  response  to  stimulator  cells  that 
express class I llgands of Ly49A. 
Materials  and Methods 
Generation of Ly49A  Transgenic Mice.  A  Ly49A cDNA  clone 
was isolated from the C57BL/6 (B6)-derived thymoma EL-4 us- 
ing reverse  transcriptase  and the polymerase chain reaction (1KT- 
PC1K) with Ly49A-specific primers  containing an EcoRI site (8). 
Compared with  the published Ly49A sequence  (2), our cDNA 
contained two silent base pair changes,  and one change that re- 
sulted in a subsntutxon  at position 106 of Met to Ile. This armno 
acid substitution,  however, was also found in Ly49A cDNAs we 
isolated from B6 A-LAK cells. The Ly49A cDNA clone was sub- 
cloned into the class I promoter expression  cassette  (15) and in- 
jected into fertdized (B6  ×  CBA/J)F  2 eggs. Transgenlc founder 
mice were idennfied by Southern blotting with an Ly49A cDNA 
probe and by staining  penpheral blood lymphocytes with FITC- 
labeled  anti-Ly49A mAbs A1  or JR9-318.  B6  backcross  mice 
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(28-14-8s)  or  H-2K  k  (15-5-5,  PharMmgen,  San  Diego,  CA). 
The allotype of the NK complex on chromosome 6 was moni- 
tored with the B6 allele-specific mAb PK136 (anti-NKl.1). The 
mice used had been backcrossed two or three times to B6 mice, 
were homozygous H-2  b/b, and were homozygous for the B6 NK 
gene complex. 
Flow Cytometry.  5  X  l0  s  nylon  wool  nonadherent  spleen 
cells  from  individual mice  were  stained  with  PE-labeled  goat 
anti-mouse  IgG  (Southern  Bxotechnology,  Birmingham  AL). 
Free binding sites were saturated with mouse IgG before addanon 
ofPE-conjugated anti-CD3 (PharMingen) and biotinylated PK136 
(anti-NKl.1). The  washed  cells  were  incubated with  streptavi- 
din-Tricolor (Caltag Laboratories, South San Francisco, CA) plus 
FITC-labeledJlL9-318 (anti-Ly49A) (4). Lymph node cells were 
stained with PE-conjugated anti-CD4  (PharMingen) plus FITC 
labeled anti-CD8 (Caltag). Alternatively, lymph node cells were 
stained with PE-conjugated anti-CD4, anti-CD8, or anti-Ig fol- 
lowed by FITC-labeledJ1K9-318.5 X  104 to 10  s events were an- 
alyzed on an EPICS XL  (Coulter, Hialeah, FL)  flow cytometer. 
Expression  of Ly49A  on  NK  cells  was  assessed  by  gating  on 
NKI.1 +  CD3-  Ig  cells.  Graphics  were  generated  using  the 
WmdMi software (John Trotter, Salk Institute, La Jolla, CA). 
Killer Assay.  Spleen cells  were  passed  over nylon wool col- 
umns  and  nonadherent  cells  were  cultured  m  P,  PMI-1640 
(GIBCO  BRL,  Gaithersburg,  MD)  containing 250  ng/ml  re- 
combinant interleukm-2. LAK cells were harvested at day 3, and 
incubated in duplicate for 4  h  with  1  ×  104 SlCr-labeled target 
cells,  either R8.15 tumor cells,  which express only the D b class I 
molecule, or Da-transfected R_8.15 cells (16). 
Mixed Lymphocyte Reactions.  Nylon wool nonadherent lymph 
node cells  were  enriched for CD4  +  T  cells  by treating the cells 
with  AD4(15)  (anti-CD8)  ascites  fired  and rabbit complement, 
followed by removal of dead cells over a ficoll gradient.  1  ×  10  s 
Ly49A-ex'pressing  CD4 + T cells (82% pure) or control CD4 + T cells 
(87% pure) were stimulated with 2  ×  l0  s irradiated (2,000 cads) 
spleen cells from which T  cells had been depleted with mAb JiJ 
(ann-Thy 1) and rabbit complement. No cytoklnes were added. 
After  4  d,  the  cultures  were  pulsed  overnight  with  0.5  IxCi 
[JH]thymidine/well. 
Bone Marrow Graft Rejection.  Recipient B10.D2 and 8- to 12- 
week-old  Ly49A  transgenac  mice  or  control  littermates,  back- 
crossed three times to B6 mace,  were irradiated (950 rads  from a 
137Cs source)  and inoculated intravenously with  5  ×  106  bone 
marrow cells from B6 or B10.D2 mice, or from [32m  /  B6. Re- 
cipient mice were injected lntraperltoneally five days later with 
3 I.LC1 of 12SI-labeled 5-iodo-2' deoxyuridine (12sI-UdR). Isotope 
incorporation in the recipient spleens was determined 24 h later, 
after rinsing the spleens with PBS. For NK cell depletion, recipi- 
ent mice were injected intraperitoneally 24 h  prior to lrradmtion 
and bone marrow  transfer with  either  200  b~g of mAb  PK136 
(antl-NKl.1, mouse IgG2a) or the isotype matched control mAb 
14-4-4 (anti-MHC class II E k, mouse IgG2a). 
Results and Discussion 
A  mouse  Ly49A  cDNA  clone  was  isolated  from  the 
C57BL/6  036) thymoma EL-4 and inserted into the class I 
promoter/immunoglobulin  enhancer expression  cassette  (15) 
to  generate  transgenic mice.  A  transgenic  036  ×  CBA/J)F  2 
founder,  with  a  high  (>15)  transgene  copy  number,  was 
back-crossed  three  times to  B6  (H-2  b)  mice  to  establish a 
transgenic line (fine No.  2).  The transgenic mice and non- 
transgenic  littermates  contained  a  comparable  frequency 
(Fig.  1 A) and number (1.0  +  0.4  ×  106,  n  =  6 vs. 0,9  + 
0.3  ×  10  6, n  =  4, respectively)  of NK cells, indicating that 
transgene expression did not prevent NK cell development. 
Approximately  20%  of NK  cells  in  nontransgenic  litter- 
mates expressed Ly49A (Fig.  1 A), similar to the proportion 
in B6 mice  (3). In contrast, virtually all NK cells (>98.0%) 
in  transgenic  mice  expressed  Ly49A  on  the  cell  surface 
(Fig.  1 A).  Importantly, the cell surface expression levels of 
Ly49A on NK cells derived from transgenic mice and non- 
transgenic littermates were not significantly different, as de- 
termined by staining with the  anti-Ly49A mAbs JR9-318 
(mean fluorescence intensity (MFI)  94  +  12 vs.  105  +  7, 
respectively) or A1  (data not shown). 
The  Ly49A  transgene  was  expressed  not  only  by  NK 
cells,  but also  on  the  surface  of CD4 +  and CD8 +  T  cells 
(Fig.  1  /3).  The peripheral  (Fig.  1  B)  and thymic  (data not 
shown)  T  cell compartments  appeared  normal,  suggesting 
that the transgene did not alter T  cell development in H-2  b 
,nice.  Furthermore,  transgene  expression  was  detected  on 
TCRy8 + and NK1.1 + T  cells (data not shown) and at vari- 
able levels  on B  cells  (Fig.  1  B).  Transgenic  macrophages 
expressed  little or  no  Ly49A  on  the  cell surface  (data  not 
shown).  These  results  extend  a  prev,ous  report  that  non- 
NKI.1 +  cells  can  support  cell  surface  expression  of Ly49 
receptors  (6,  13). 
The  specificity and function of the  Ly49A  transgene  in 
NK  cells  was  estabhshed  by  its  ability to  confer  H-2D  a- 
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Figure  1.  Analysis  of Ly49A 
transgemc nnce. (A) Nylon wool 
nonadherent  spleen  cells from 
Ly49A transgenlc m]ce and non- 
transgemc httermates contained a 
similar  frequency  of  NK  cells. 
Ly49A expression defines a sub- 
set of ~20% of NK cells m non- 
transgenlc  httemlates,  whereas 
v]rtually all transgemc NK  cells 
expressed Ly49A. (B) Compara- 
ble  frequencms  of  CD4  +  and 
CD8 + T  cells were  observed in 
lymph  nodes  from  transgemc 
mice  and  nontransgemc  htter- 
mates. Compared with unstained 
lymph node cells (filled histqcrams), 
nontransgenlc CD4  + and  CD8 + 
T  cells &d  not  express Ly49A, 
whereas all CD4 + and CD8 + T 
cells from  transgenlc  mice  ex- 
pressed Ly49A. Ly49A levels on 
surface  ]mmunoglobulln-pos]- 
tlve (slg  +) B cells were variable. 
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Figure 2.  Ly49A transgene expressmn confers MHC class I Da-speclfiC 
inhibmon  to unfractionated NK cells The results of two independent ex- 
periments  are  shown.  Interleukln-2 activated  k]ller cells from  Ly49A 
transgemc and nontransgenic littermates efficiently lysed the NK cell~en- 
stove tumor cell line R8.15, which expresses only the D b class I molecule. 
P-.8.15 cells transfected with the D d class I molecule were resistant to lysis 
by killer cells from Ly49A-transgemc mice but were lysed by killer cells 
from nontransgenic httermates 
specific inhibition to unfractionated interleukin-2-activated 
NK  cells. Whereas  NK  ceils from Ly49A-transgenic mice 
(H-2  b)  and  control  nontransgenic littermates  (H-2  b)  effi- 
ciently lysed the tumor target  cell II.8.15,  the lytic activity 
of transgenic NK  cells was specifically inhibited by D '~ ex- 
pression  as  shown  by  their  failure  to  lyse  Dd-transfected 
R8.15  cells  (Fig.  2).  Similar  results  were  obtained  with 
freshly  isolated,  poly  I/C-activated  NK  cell  preparations 
(data  not  shown).  These  results  represent  direct  evidence 
that Ly49 molecules are sufficient to confer class I-specific 
inhibition of target cell lysis to  NK  cells. A  previous study 
employing viral-mediated gene transduction reached a sim- 
ilar  conclusion with  respect  to  the  structurally  unrelated 
human KIlL gene family (17). 
Previous studies have demonstrated that NK  cells me&ate 
the rejection by irradiated mice of allogeneic or class  I-defi- 
cient bone marrow cells, and of parental-type marrow grafts 
by F 1 hybrids of H-2 disparate mouse stratus (18). To estab- 
lish  the  role  of Ly49  receptors  in  NK  cell specificity and 
function  in  vivo,  we  determined  the  effects  of  Ly49A 
transgene  expression  on  the  capacity  of  irradiated  H-2  b 
mice  to  reject  an  allogeneic  H-2 d bone  marrow  graft,  a 
reaction that is mediated by NK cells (19). Marrow engraft- 
ment was  monitored by the incorporation of 5-[12sI]iodo  - 
2'-deoxyuridine in spleen cells, indicating donor cell pro- 
liferation (18).  Whereas  nontransgenic H-2  b mice rejected 
the allogeneic H-2 a (B10.D2) bone marrow grafts, Ly49A- 
transgenic H-2  b mice  completely  accepted  these  grafts,  as 
demonstrated by the high level of isotope incorporation in 
their  spleens  (Fig.  3  A).  As  expected,  both  Ly49A  trans- 
gemc  and  nontransgenic mice  accepted  H-2-identical B6 
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Ly49A transgemc H-2  b mice are unable to reject an H-2  a 
bone marrow allograft. (A) P,  ejectlon of bone marrow grafts by irradiated 
mice was assayed with the splemc ~2sI-UdR Incorporation assay, ,n which 
low levels of ISOtope incorporation  reflect rejection of the graft, and high 
levels of incorporation reflect graft acceptance. Each symbol represents an 
Individual recipient  animal  Four recipient  mace were  used per expen- 
mental group in most cases. The transgenlc mace,  like the control mace, 
accepted H-2-1dentical (H-2 b) grafts. In contrast with nontransgenlc litter- 
mates, Ly49A-transgemc H-2  b mice  were  unable  to  reject  H-2  a bone 
marrow grafts This was not due to a general inability to reject bone mar- 
row cells, since grafts derived from [32m-deficient mice were readily re- 
lected  (B) Bone marrow graft rejection in Ly49A transgemc mice is me- 
&ated by NK1 1  + cells since depletmn  of NK1 1  + cells results m  the 
inablhty to reject grafts derived from {32m-deficient  mice. 
(H-2  b)  bone  marrow  grafts.The  Ly49A-transgenic  mice 
retained  the  capacity  to  reject  bone  marrow  grafts  from 
class I-deficient (i.e.,  [32m-)  mice  (20)  (Fig.  3  A),  a  reac- 
non that was prevented by pretreating the mice with anti- 
NKI.1  antibody, but not with irrelevant (anti-MHC  class 
II  I-E)  antibody  (Fig.  3  B).  Hence,  the  transgene specifi- 
cally prevented rejection of H-2 d bone marrow grafts,  and 
did not affect NK-mediated rejection of 132m- bone mar- 
row grafts.  This experiment demonstrates that the capacity 
to reject H-2  d grafts is prevented when Ly49A is expressed 
on all NK  ceils,  as  opposed  to  on a  subset of NK  cells as 
observed in normal mice.  Therefore,  a  significant conclu- 
sion of our results is that the alloreactivity observed in the 
NK  cell  compartment  is  due  to  the  failure  of many NK 
cells to  express  a  given class I-specific inhibitory receptor, 
i.e.,  to  the  fact  that  Ly49  receptor  expression is  normally 
restricted to NK cell subsets. 
The  demonstration  that  the  Ly49A  transgene  prevents 
rejection of H-2 d bone marrow  cell grafts  provides  direct 
evidence of a  role  for  Ly49  receptors  in vivo.  A  role  for 
Ly49  receptors  in bone  marrow  cell  rejection was  previ- 
ously inferred from in vitro cytolysis experiments that mir- 
ror the specificity  of bone marrow cell rejecnon (9).  Some 
caution is warranted in equating the  cytolysis experiments 
with bone marrow cell rejection; however, when it is con- 
sidered that marrow rejection remains largely intact in mice 
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Figure 4.  Ly49A  transgene expression m CD4 ÷ T cells prevents the al- 
logenelc mixed lymphocyte reaction. CD4 + responder T ceils from B6 
backcross (H-2  b) Ly49A transgemc nnce proliferated m response to ~2m- 
deficient B10.BR  stimulator spleen cells. In  contrast, the  response to 
[32m  + B10.BR  stimulators, which  express the  D  k Ly49A hgand, was 
strongly inhibited. CD4 + T cells from nontransgenlc httermates prohfer- 
ated in response to [32m  as well as [32m  + B10.13R smnulator cell popu- 
lations Data represent mean values + standard deviation of quadruphcate 
deternnnatlons based on two experiments. 
that lack perforin- or Fas-mediated cytotoxic function (21). 
Furthermore, the possibility that MHC  recognition by NK 
cells  can  in  some  cases  induce,  rather  than  inhibit  bone 
marrow rejection is not reflected by the in vitro assays (22, 
23).  A  role for Ly49 receptors in bone  marrow cell rejec- 
tion was  also previously suggested by correlative evidence 
that  Ly49C ÷  NK  cells are  essential for  rejection of H-2  d 
bone marrow grafts by H-2  b mice (24). Since cells express- 
ing Ly49C are present in normal numbers in Ly49A trans- 
genic mice (data not shown), a hkely explanation of our re- 
sults is that Ly49A transgene expression confers Dd-specific 
inhibition to  all Ly49C ÷  NK  cells, thus  preventing  these 
cells from rejecting the H-2 d bone marrow cell allograft. 
To address whether Ly49 receptors can confer class I-spe- 
cific inhibition to lymphocytes other than NK cells, we ad- 
dressed the  effects  of Ly49A transgene  expression  on  the 
proliferative response of conventional CD4 ÷ T  cells, most 
of which  are  normally Ly49A-  (Fig.  1  B),  to  allogenelc 
class  II  molecules.  CD4 +  T  cell-enriched responder cells 
from transgenic and nontransgenic mice responded equiva- 
lently  to  stimulation  with  [32m-deficient  B10.B1K  spleen 
cells (Fig. 4).  These  stimulator cells present the  allogeneic 
A k and E k class II molecules, but do not express class I mol- 
ecules. Stimulator cells from class I + B10.BR  mice, which 
also express A k and E k but express in addition the Ly49A- 
specific D k class I  molecule  (11),  ehcited a  good response 
from nontransgenic  CD4 + T  cells, but the response of the 
Ly49A-transgenic CD4 + T  cells was completely inhibited. 
Thus,  the Ly49A-class I interaction can even inhibit T  cell 
receptor-mediated  responses  to  allogeneic  class  II  mole- 
cules.  Similar results  were  obtained  when  we  tested  the 
CD8 +  T  cell  proliferative  response  to  allogenelc  MHC 
molecules (data not shown). 
The  finding  that  Ly49A  functions  in  T  cells  indicates 
that no  additional NK cell-specific molecules are required 
for Ly49 receptor activity, and suggests that the relevant in- 
hibitory signaling pathways are conserved in NK and T  cells 
and perhaps  all lymphoid cells.  In line with  this  observa- 
tion,  previous  studies  in  the  human  system  demonstrated 
KIR-mediated,  class  I-specific  inhibition  of cytolysis  by 
certain T  cell clones (25). The recent implication of the ty- 
rosine phosphatases PTPlC  and/or PTPlD  in the  down- 
modulation or prevention of immune responses by B  cells, 
T  cells, and NK cells lends further support for this notion 
(26-28). With regard to Ly49A, the retention of the signal- 
ing pathway  in  T  cells is  of particular interest  because  a 
small fraction oft  cells express Ly49 receptors on their sur- 
face (4, 5).  Therefore, besides regulating NK cell function, 
Ly49A-class  I  interactions  may  be  important  in  normal 
mice for the regulation of some T  cells (25). 
In  conclusion,  we  have  demonstrated  that  the  Ly49A 
molecule is the only NK cell-specific receptor required to 
confer inhibitory class I specificity to NK cells and T  cells, 
and most significantly, that these receptors regulate NK cell 
function  in  vivo.  The  results  suggest  that  Ly49  receptors 
regulate  multiple  cellular  effector  functions,  and  do  not 
represent  accessory receptors for  class  I  recognition.  Fur- 
thermore, the data indicate that the expression of Ly49 re- 
ceptors by NK  cell subsets in normal mice  is essential for 
the discrimination of class I-different cells. This property is 
probably necessary to allow NK cells to attack variant cells 
in  which  the  expression  of some  but  not  all  host  class  I 
molecules  are  repressed  due  to  infection,  mutation,  or 
transformation (29). 
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